RPA-601 by Rocket Pharmaceuticals for Cardiomyopathy: Likelihood of Approval

Or­chard Ther­a­peu­tics’ ul­tra-rare dis­ease drug Len­meldy is vault­ing to the list of most ex­pen­sive drugs ever with a whole­sale ac­qui­si­tion cost of $4.25 mil­lion for

Aphaia Pharma’s CEO Steffen Sebastian-Bolz discussed problems with obesity trial patient recruitment. Credit: Alexey Krukovsky via Getty Images, Following plans to add cohorts in an